跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Approvals
/
Health Canada
/
RYMTI
Authorized
STANDARD
RYMTI
lupin pharma canada limited
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
ee32599f02c357e1
Company
lupin pharma canada limited
Type
Standard
Approval Details
Approval Id
ee32599f02c357e1
Drug Approval Canada Name
RYMTI
Product Name
RYMTI
Status
Marketed
Status Date
2024-04-05
Original Market Date
2024-04-05
Din
02530309
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Subcutaneous
Schedule
Prescription , Schedule D
Ahfs
90:24.16.92
Atc Original
L04AB01 ETANERCEPT
Atc Name
l 04 ab 01
Aig Number
0151564001
Company Name
lupin pharma canada limited
Company Address
550-1111 Rue St-Charles Ouest, Longueuil, Quebec, Canada, J4K 5G4
Active Ingredients
ETANERCEPT
50 MG / 1 ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
ee32599f02c357e1
Type
Standard
Back to Health Canada Approvals
RYMTI - Health Canada Drug Approval Details